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S U M M A R Y
Objectives: To investigate the prevalence, incidence of abnormal liver function tests (LFTs), and mortality
during anti-TB treatment in patients multi-infected with HIV, tuberculosis (TB), and hepatitis virus
(hepatitis B virus (HBV) and hepatitis C virus (HCV)).
Methods: Three hundred and sixty-one HIV-positive TB patients were enrolled and divided into an HIV/
TB group, HIV/TB/HBV group, and HIV/TB/HCV group; 1013 HIV-negative TB patients were selected
randomly as controls.
Results: One hundred and seventeen (32.4%) HIV-positive TB patients were infected with HBV and/or
HCV, compared with 90 (8.9%) HIV-negative TB patients (p = 0.000). HIV-positive TB patients had a
higher incidence of anti-TB drug-induced hepatotoxicity than HIV-negative TB patients (4.2% vs. 1.0%,
odds ratio (OR) 4.348, 95% conﬁdence interval (CI) 1.935–9.769, p = 0.000). The incidence of abnormal
LFTs in the HIV/TB/HBV group and HIV/TB/HCV group were signiﬁcantly higher than in the HIV/TB group
(40.7% vs. 11.1%, OR 5.525, 95% CI 2.325–13.131, p = 0.000; 20.0% vs. 11.1%, OR 2.009, 95% CI 1.057–3.820,
p = 0.031). A total of 68.4% of patients with HBV-DNA >1.0  105 copies/ml and 42.9% of patients with
HCV-RNA >1.0  105 copies/ml had abnormal LFTs. Twenty-three (19.7%) patients multi-infected with
HIV, TB, and hepatitis virus died during anti-TB treatment.
Conclusions: HIV, HBV, and HCV are risk factors for the development of abnormal LFTs and mortality
during anti-TB treatment. TB patients co-infected with HIV and hepatitis virus need close follow-up.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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AIDS, tuberculosis (TB), and chronic viral hepatitis (hepatitis B
and C) are among the most prevalent infectious diseases in the
world, especially in developing countries. One-third of the world
population is infected with latent TB and approximately 5–10% will
develop active TB during their lifetime. However, the risk of
developing active TB in HIV-positive patients increases to 5–10%
annually.1 From 1995 to 2012, the positivity rate of HIV in TB
patients increased from 4.2% to 13%.2 AIDS and viral hepatitis
(hepatitis B and C) share risk factors and modes of transmission.3
Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is
common in patients infected with HIV.4* Corresponding author. Tel./ Fax: +86 027 67812880.
E-mail address: ZNACT@126.com (X.-e. Gui).
http://dx.doi.org/10.1016/j.ijid.2014.06.020
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).China is one of the highest TB burden countries in the world,
ranking second in total number of TB patients. One million new
cases of TB were reported in China in 2012, with 7300 (0.7%) of
these patients co-infected with HIV.2 Viral hepatitis is also
endemic in China. The positive rates of hepatitis B surface antigen
(HBsAg) and antibodies to HCV (anti-HCV) were reported to be
10.2% and 85.9%, respectively, among HIV-positive patients with
transmission through plasma donation. The HIV/HBV/HCV triple-
infection rate among plasma donors was 6.9%.5
Most patients with active TB disease can be treated safely and
effectively through the directly-observed therapy strategy
(DOTS). However, drug-induced hepatotoxicity (DIH) is one of
the most frequent and serious side effects.6 Medications used to
treat HIV, TB, and opportunistic infections are often hepatotoxic.
Thus, multi-infection with HIV, TB, and HBV or HCV has increased
the clinical complexity of managing patients and poses unique
challenges to clinicians and public health ofﬁcials. Nevertheless,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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limited.
We conducted an observational study to investigate the
prevalence of HIV, TB, and viral hepatitis in hospitalized patients.
We also evaluated the impact of HIV, HBV, and HCV infections on
hepatic function and mortality in TB patients during anti-TB
treatment.
2. Materials and methods
2.1. Study individuals
Patients hospitalized in Zhongnan Hospital of Wuhan Univer-
sity were screened for HIV and TB, and patients with active TB at
the Wuhan Tuberculosis Control Center were screened for HIV
from February 2012 to February 2013. HIV-positive TB patients in
Zhongnan Hospital between July 2003 and February 2013 were
included in this study. HIV-negative TB patients at the Wuhan
Tuberculosis Control Center were selected randomly as a control
group.
Patients with abnormal liver function tests (LFTs) prior to TB
treatment were excluded. HIV-positive TB patients were divided
into an HIV/TB group, HIV/TB/HBV group, and HIV/TB/HCV group.
HIV-negative TB patients were divided into a TB group, TB/HBV
group, and TB/HCV group (Figure 1). The following data were
collected: age, gender, types of TB, transmission route of HIV, CD4+
T cell counts, and treatment for active TB and HIV.
2.2. Laboratory studies
At the beginning of anti-TB treatment, blood samples were
tested for HIV, HBV markers (hepatitis B surface antigen, HBsAg;
antibodies to hepatitis B surface antigen, HBsAb; hepatitis B e
antigen, HBeAg; antibodies to hepatitis B e antigen, HBeAb; and
antibodies to hepatitis B core antigen, HBcAb), anti-HCV, and LFTs
(alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and total bilirubin). Patients who were positive for HBsAg
and anti-HCV were also tested for HBV-DNA and HCV-RNA. HIV
antibody, HBV markers, and anti-HCV tests were performed by
ELISA (Shanghai Kehua Bio-Engineering Co., Ltd, China). CD4+ T
lymphocyte cell counts (Beckman coulter ﬂow cytometry, USA)
were tested in HIV-positive patients. HBV-DNA and HCV-RNA
were tested using a PCR-ﬂuorescence detection kit (Shanghai
Kehua Bio-Engineering Co., Ltd, China). Positivity was set atFigure 1. Diagram of the study population. HIV, human immunodeﬁciency virus;
TB, tuberculosis; LFTs, liver function tests; HBV, hepatitis B virus; HCV, hepatitis C
virus; HIV-pos TB-pos, HIV-positive TB patients; HIV-neg TB-pos, HIV-negative TB
patients; HBV-neg HCV-neg, without HBV and HCV infection; HBV-pos, with HBV
infection; HCV-pos, with HCV infection; HBV-pos HCV-pos, with HBV and HCV
infection.HBV-DNA 500 copies/ml and HCV-RNA 1000 copies/ml, in
accordance with the manufacturer’s instructions.
2.3. Diagnosis of disease
The diagnosis of active TB was established using at least one of
the following criteria: (1) Conﬁrmed TB: positive culture of
sputum, bronchial lavage ﬂuid, pleural ﬂuid, or samples from
organs other than the lung. (2) Probable TB: tuberculous
granuloma or caseous necrosis in biopsy materials and a good
response to anti-TB treatment. (3) Possible TB: clinical manifesta-
tions, pulmonary inﬁltrates on chest X-ray or computed tomogra-
phy (CT) scan, positive immunological test results, and a good
response to anti-TB treatment.
HIV infection was diagnosed by a positive anti-HIV test and
conﬁrmed by Western blot. HBV infection was diagnosed by a
positive serum HBsAg. HCV infection was diagnosed by a positive
serum anti-HCV and HCV-DNA.
2.4. Treatment regimen
The recommended treatment protocol for newly diagnosed TB
patients without HIV infection consisted of a daily drug combina-
tion of isoniazid (INH), rifampin (RIF), ethambutol (EMB), and
pyrazinamide (PZA) for 2 months, followed by daily INH and RIF for
an additional 4 months. A 9–12-month regimen consisting of 3–4
months of therapy with INH, RIF, EMB, and PZA, followed by 6–8
months of therapy with INH and RIF was recommended for HIV-
positive TB patients. Most patients at our hospital initially received
daily INH (300 mg), RIF (450–600 mg), EMB (750–1200 mg), and
PZA (1500 mg).
In HIV-positive TB patients not on combined antiretroviral
therapy (cART), anti-TB treatment was administered ﬁrst. cART
was initiated within the ﬁrst 8 weeks of anti-TB treatment. Patients
with CD4 counts <50 cells/ml received cART within the ﬁrst
2 weeks of anti-TB treatment. Combined antiretroviral regimens
included zidovudine (AZT) or tenofovir disoproxil fumarate (TDF)
plus lamivudine (3TC) and efavirenz (EFV). Nevirapine (NVP) was
avoided in HIV-positive patients on anti-TB treatment.7
2.5. Monitoring and deﬁnition of abnormal LFTs
Liver function was tested every 2 weeks during the ﬁrst month
after the initiation of anti-TB treatment, and monthly thereafter until
the completion of anti-TB treatment. Monitoring was performed
more frequently if LFTs were abnormal. The treatment of DIH was
undertaken in the generally accepted manner.8 The mortality of
patients with TB was assessed at the end of anti-TB treatment.
Abnormal LFTs were diagnosed if the levels of serum
transaminases were >46 IU/l. DIH was deﬁned as a serum
transaminase level exceeding three times the upper limit of
normal, or a total bilirubin level >1.5 mg/dl.
2.6. Classiﬁcation of death
(1) TB: died of massive hemoptysis or respiratory failure. (2) AIDS:
died of an opportunistic infection (except TB) or cancer (such as
lymphoma, cervical carcinoma, or Kaposi’s sarcoma) associated with
AIDS. (3) Hepatotoxicity: died of DIH, severe hepatitis, or advanced
liver cirrhosis. (4) Other reason: died of other diseases or suicide.
2.7. The principle of medical ethics
The study was approved by the ethics committees of Zhongnan
Hospital of Wuhan University and informed consent was obtained
from all subjects.
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Continuous variables were recorded as the median (inter-
quartile range, IQR) and analyzed using the non-parametric Mann–
Whitney U-test. The rates were compared using the Pearson Chi-
square test or Fisher’s exact test. The statistical analysis was
performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Differences
were considered signiﬁcant when p-values were <0.05.
3. Results
3.1. Prevalence of HIV and TB
A total of 7448 hospitalized patients with active TB and 24 326
hospitalized patients without active TB were screened for HIV.
The positive rate of HIV in patients with TB was signiﬁcantly
higher than that in patients without TB (0.5% vs. 0.2%, p = 0.000).
Meanwhile, 325 HIV-positive hospitalized patients and 7132 HIV-
negative hospitalized patients were screened for TB. The incidence
of TB in HIV-positive hospitalized patients was signiﬁcantly higher
than that in HIV-negative hospitalized patients (15.7% vs. 1.0%,
p = 0.000).
3.2. Infection rate of HBV and HCV
Three hundred and seventy-ﬁve HIV-positive TB patients were
enrolled in this study. Fourteen participants were excluded
because their LFTs were abnormal prior to TB treatment.
Meanwhile, 1013 HIV-negative TB patients were selected
randomly as a control group (Figure 1). One hundred and
seventeen (32.4%) HIV-positive TB patients were positive for
HBsAg and/or anti-HCV, compared with 90 (8.9%) HIV-negative
TB patients (p = 0.000). Among all HIV-positive TB patients, 27
(7.5%) were HBV co-infected, 95 (26.3%) were HCV co-infected,
and ﬁve (1.4%) were both HBV and HCV co-infected. The infection
rate of HCV in HIV-positive TB patients was signiﬁcantly higher
than that in HIV-negative TB patients (26.3% vs. 1.7%, p = 0.000)
(Table 1).Table 1
Baseline characteristics of TB patients
HIV-neg
TB-pos group
HIV-neg TB-pos subgroup 
TB TB/HBV T
Number (%) 1013 923 (91.1) 81 (8.0) 1
Age, years, median (IQR) 43 (27–54) 34 (23–49) 46 (31–57) 4
Gender, n (%)
Male 760 (75.0) 683 (74.0) 69 (85.2) 1
Female 253 (25.0) 240 (26.0) 12 (14.8) 
CD4 + T cell count, cells/ml 486 (378–646) 486 (378–646) - 
cART, n (%) 
Types of TB, n (%)
Pulmonary TB 775 (76.5) 703 (76.2) 64 (79.0) 1
Extrapulmonary TB 53 (5.2) 51 (5.5) 1 (1.2) 
Miliary/disseminated TB 185 (18.3) 169 (18.3) 16 (19.8) 
Diagnosis, n (%)
Conﬁrmed TB 448 (44.2) 
Probable TB 51 (5.0) 
Possible TB 514 (50.7) 
Transmission route of HIV, n (%)
Sexual contact 
Blood transmissionc
Mother-to-child 
TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatitis C virus; cART, combined antire
a Compared with TB/HCV group, p = 0.000.
b Compared with HIV-neg TB-pos group, p = 0.000.
c Including plasma donors, blood recipients, and injecting drug users.3.3. Incidence of abnormal LFTs and DIH
The incidences of abnormal LFTs in HIV-positive and HIV-
negative TB patients were 10.2% and 9.9%, respectively. There was
no statistical difference between them (odds ratio (OR) 1.043, 95%
conﬁdence interval (CI) 0.700–1.552, p = 0.837). However, HIV-
positive TB patients had a higher incidence of DIH than HIV-
negative TB patients (4.2% vs. 1.0%, OR 4.348, 95% CI 1.935–9.769,
p = 0.000).
Among HIV-positive TB patients with and without cART, no
statistically signiﬁcant difference in the incidences of abnormal
LFTs was found during anti-TB treatment (16.3% vs. 14.1%, OR
1.188, 95% CI 0.661–2.136, p = 0.564). In the HIV/TB group and HIV/
TB/HCV group, the incidence of abnormal LFTs of patients on cART
was slightly higher than that of patients not on cART. However, the
opposite result was seen in the HIV/TB/HBV group; 27.3% of the
patients on cART exhibited abnormal LFTs, compared with 53.3%
of the patients not on cART (Table 2).
The incidences of abnormal LFTs and DIH in the HIV/TB/HBV
group were much higher than those in the HIV/TB group (40.7% vs.
11.1%, OR 5.525, 95% CI 2.325–13.131, p = 0.000; 18.5% vs. 2.5%, OR
9.015, 95% CI 2.545–31.930, p = 0.000). The incidence of abnormal
LFTs in the HIV/TB/HCV group was much higher than that in the
HIV/TB group (20.0% vs. 11.1%, OR 2.009, 95% CI 1.057–3.820,
p = 0.031) (Figure 2).
A total of 68.4% of patients with HBV-DNA >1.0  105 copies/ml
and 42.9% of patients with HCV-RNA >1.0  105 copies/ml had
abnormal LFTs (OR 8.125, 95% CI 2.668–24.740, p = 0.000). In the
HIV/TB/HBV group, the incidence of abnormal LFTs in patients with
HBV-DNA >1.0  105 copies/ml was signiﬁcantly higher than that
in patients with HBV-DNA <1.0  105 copies/ml (77.8% vs. 23.1%,
OR 11.667, 95% CI 1.527–89.121, p = 0.027) (Table 3). Of nine
patients with HBV-DNA >1.0  105 copies/ml, six had undetect-
able HBV-DNA and the other three patients had a signiﬁcant
decline in HBV-DNA levels after 6 months of cART. LFTs of all
patients with HBV-DNA >1.0  105 copies/ml also normalized
within 6 months of cART. In the HIV/TB/HCV group, the incidence
of abnormal LFTs in patients with HCV-RNA >1.0  105 copies/ml
was signiﬁcantly higher than in patients with HCV-RNA <1.0  105HIV-pos
TB-pos group
HIV-pos TB-pos subgroup
B/HCV HIV/TB HIV/TB/HBV HIV/TB/HCV
7 (1.7) 361 244 (67.6) 27 (7.5) 95 (26.3)a
6 (43–56) 40 (32–46) 40 (31–47) 39 (35–47) 37 (33–45)
5 (88.2) 247 (68.4) 169 (69.3) 20 (74.1) 60 (63.2)
2 (11.8) 114 (31.6) 75 (30.7) 7 (25.9) 35 (36.8)
- 58 (14–153)b 62 (17–155) 36 (12–131) 50 (19–110)
141 (39.1) 94 (38.5) 11 (40.7) 40 (42.1)
4 (82.4) 188 (52.1) 127 (52.0) 10 (37.0) 53 (55.8)
2 (11.8) 76 (21.1) 51 (20.9) 5 (18.5) 22 (23.2)
1 (5.9) 97 (26.9) 66 (27.0) 12 (44.4) 20 (21.1)
76 (21.1)
35 (9.7)
250 (69.3)
204 (56.5) 170 (69.7) 20 (74.1) 16 (16.8)
153 (42.4) 71 (29.1) 7 (25.9) 78 (82.1)
4 (1.1) 3 (1.2) 0 1 (1.1)
troviral therapy.
Table 2
The incidence of abnormal LFTs in HIV-positive TB patients treated with anti-TB
drugs alone and combined with cART, n (%).
ATT without cART ATT with cART p-Value
HIV/TB 14/150 (9.3%) 13/94 (13.8%) 0.278
HIV/TB/HBV 8/15 (53.3%) 3/11 (27.3%) 0.246
HIV/TB/HCV 10/55 (18.2%) 9/40 (22.5%) 0.603
Total 31/220 (14.1%) 23/141 (16.3%) 0.564
LFTs, liver function tests; TB, tuberculosis; cART, combined antiretroviral therapy;
ATT, anti-tuberculosis therapy; HBV, hepatitis B virus; HCV, hepatitis C virus.
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p = 0.014) (Table 3).
3.4. Mortality
The mortality of TB patients was assessed at the end of anti-TB
treatment. The mortality rate in HIV-positive TB patients was
signiﬁcantly higher than that in HIV-negative TB patients (13.6%
vs. 0.9%, OR 17.520, 95% CI 8.510–36.068, p = 0.000). The totalFigure 2. (A) Incidence of abnormal liver function tests (LFTs) during anti-TB treatment.
human immunodeﬁciency virus; TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatit
Table 3
Incidence of abnormal LFTs in TB patients during anti-TB treatment, n (%)
Hepatitis viral load TB/HBV HIV/TB/HBV TB/H
HIV
<1.0  105 copies/ml 13/63 (20.6) 3/13 (23.1) 16/7
>1.0  105 copies/ml 6/10 (60.0) 7/9 (77.8) 13/1
p-Value 0.016 0.027 0.00
LFTs, liver function tests; TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatitis C viru
Table 4
Mortality of patients with HIV, TB, HBV, and/or HCV multi-infection, n (%)
HIV-neg TB-pos group
9/1013 (0.9)
TB
n = 923
TB/HBV and/or
n = 90
Died of TB 5 (0.5) 1 (1.1) 
Died of AIDS 0 0 
Died of hepatotoxicity 0 0 
Died of other reason 3 0 
Total mortality 8 (0.9) 1(1.1) 
TB, tuberculosis; HBV, hepatitis B virus; HCV, hepatitis C virus.
a Compared with HIV-neg TB-pos group, p = 0.000.
b Compared with HIV/TB group, p = 0.013.
c Compared with HIV/TB group, p = 0.019.mortality rate in the HIV/TB/HBV and/or HCV group was 19.7%,
which was much higher than that in the HIV/TB group (OR 2.052,
95% CI 1.114–3.779, p = 0.019). In the HIV/TB/ HBV and/or HCV
group, 12 (10.3%) died from TB, 10 (8.5%) died from AIDS, and one
(0.9%) died from hepatotoxicity. More patients died from TB in the
HIV/TB/HBV and/or HCV group than in the HIV/TB group (OR 2.984,
95% CI 1.220–7.298, p = 0.013) (Table 4).
4. Discussion
Tuberculosis is the most common opportunistic infection in
HIV-infected patients. In 2012, 8.6 million new cases of TB were
reported worldwide, with 1.1 million (13%) of these patients co-
infected with HIV.2 In this study, 0.5% of TB patients were infected
with HIV, compared with 0.2% of patients without TB. On the other
hand, 15.7% of HIV-positive hospitalized patients were diagnosed
with active TB, compared with 1.0% of HIV-negative hospitalized
patients. These results show that patients with TB have a higher
HIV infection rate than patients without TB and that HIV-positive
patients are more likely to develop active TB than HIV-negative (B) Incidence of drug-induced hepatotoxicity (DIH) during anti-TB treatment. (HIV,
is C virus.).
BV and
/TB/HBV
TB/HCV HIV/TB/HCV TB/HCV and
HIV/TB/HCV
6 (21.1) 2/13 (15.4) 1/17 (5.9) 3/30 (10.0)
9 (68.4) 2/4 (50.0) 10/24 (41.7) 12/28 (42.9)
0 0.219 0.014 0.006
s.
HIV-pos TB-pos group
49/361 (13.6)a
 HCV HIV/TB
n = 244
HIV/TB/HBV and/or HCV
n = 117
9 (3.7) 12 (10.3)b
16 (6.6) 10 (8.5)
0 1 (0.9)
1 0
26 (10.7) 23(19.7)c
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patients and HIV testing in TB patients.
In China, the prevalences of HBV and HCV infection in the
general population have been reported as 7.2% and 2.2%,
respectively.9,10 In this study, the HBsAg-positive rate was 8.0%
and the anti-HCV-positive rate was 1.7% in HIV-negative TB
patients. Among HIV-positive TB patients, the HBsAg-positive rate
was 7.5% and the anti-HCV-positive rate was 26.3%. The HBV
infection rate in HIV-positive TB patients was similar to that in
HIV-negative TB patients and the general population. However, the
HCV infection rate in HIV-positive TB patients was signiﬁcantly
higher than that in HIV-negative TB patients and the general
population. A total of 82.1% of patients were infected with HIV and
HCV through blood transmission (including plasma donors, blood
recipients, and injecting drug users). Medical workers should pay
more attention to screen for hepatitis virus infection, especially
HCV infection, in HIV-positive patients and intravenous drug users.
Early detection and diagnosis of HIV and hepatitis virus infection is
advantageous to the management and treatment of TB patients.
The use of multidrug regimens for anti-TB treatment based on
the combination of IHN, RIF, EMB, and PZA has proven to be a
highly effective therapy. However, DIH associated with ﬁrst-line
anti-TB drugs is a common side effect and often necessitates the
modiﬁcation or interruption of anti-TB treatment.11 A previous
study indicated that difﬁculty tolerating anti-TB therapy was
common among people living with HIV and viral hepatitis co-
infection.12 Our study showed that compared with HIV-negative
patients, HIV-positive patients had a similar incidence of abnormal
LFTs (10.2%), but had a signiﬁcantly higher incidence of DIH (4.2%).
The reported incidences of DIH in HIV-positive patients receiving
treatment with INH, RIF, and PZA have varied considerably, ranging
from 2.0% to 36.5%.13–15 We also compared the incidences of
abnormal LFTs between patients receiving anti-TB treatment with
and without EFV-based cART. We found that there was no
signiﬁcant difference between them. This indicated that combin-
ing anti-TB treatment and EFV-based cART does not result in a
signiﬁcant increase in incidence of abnormal LFTs. Similar results
have been found in other studies, thus EFV-based cART is
recommended for HIV/TB patients receiving anti-TB treatment.7,16
Several studies have shown that hepatitis virus infection is an
independent risk factor for hepatotoxicity. Nearly 29–59% of
patients co-infected with TB and HBV and 24–41% of patients co-
infected with TB and HCV had elevated LFTs.15,17–20 However,
studies on anti-TB DIH in patients multi-infected with HIV, TB, and
hepatitis virus are limited. A previous study indicated that 45% of
HIV/TB/HCV patients developed DIH, compared with 21% of HIV/TB
patients and 24% of TB/HCV patients.20 In this study, patients co-
infected with hepatitis virus developed anti-TB treatment DIH
more commonly than patients without hepatitis virus infection.
The incidences of abnormal LFTs and DIH in the HIV/TB/HBV group
were 40.7% and 18.5%, respectively, both of which were the highest
in all groups. Further analysis revealed that patients with high
levels of HBV-DNA or HCV-RNA were more likely to exhibit
elevated LFTs during anti-TB treatment. Seven out of nine (77.8%)
patients with HBV-DNA >105 copies/ml in the HIV/TB/HBV group
had elevated LFTs during anti-TB treatment. However, The HBV-
DNA level of these nine patients declined signiﬁcantly and ALT
levels of the seven patients decreased to normal limits by 6 months
of cART. This is due to cART including 3TC and TDF, which inhibit
HBV replication effectively and beneﬁt the recovery of liver
function. This might also be the reason why the incidence of
elevated LFTs in patients with anti-TB treatment and on cART was
lower than that in patients with anti-TB treatment but not on cART.
cART including 3TC and TDF is recommended for patients co-
infected with HIV and HBV.21,22 Furthermore, 10 of 24 (41.7%)
patients with HCV-RNA >105 copies/ml in the HIV/TB/HCV grouphad elevated LFTs during anti-TB treatment. In order to reduce the
impact of HCV infection, patients co-infected with HIV and HCV
should be offered anti-HCV therapy, especially those patients with
high levels of HCV-RNA. Hepatitis viral load might be an important
predictor with regard to the risk of elevated LFTs during anti-TB
treatment in patients with HBV and/or HCV infection.
The mortality of patients with HIV, TB, and hepatitis virus
multi-infection is high because these multiple diseases are more
complicated and difﬁcult to treat. A recent study from New York
showed that patients with more than one of the diseases
mentioned above were more likely to die than patients with only
one disease.23 In our study, a greater proportion of patients multi-
infected with HIV, TB, and hepatitis virus died during the study
time period (19.7%), followed by patients with HIV/TB co-infection
(10.7%) and patients with TB/hepatitis virus co-infection (1.1%).
A limitation of our study is that the numbers of patients in the
TB/HCV group and HIV/TB/HBV group were relatively small.
Further studies with larger samples and longer follow-up times are
needed to further identify the interaction effects between HIV, TB,
HBV, and HCV.
In conclusion, HIV, TB, and chronic hepatitis virus multi-
infection are common in China. HIV, HBV, and HCV are risk factors
for the development of abnormal LFTs and mortality during anti-TB
therapy. Therefore, it is necessary to screen for HIV, HBV, and HCV
at the beginning of anti-TB treatment in TB patients. Routine
monitoring of liver function and hepatitis viral load is recom-
mended during anti-TB treatment in patients multi-infected with
HIV, TB, and hepatitis virus.
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